title: Efficacy of PTX3 and posaconazole combination in a rat model of invasive pulmonary aspergillosis.
abstract: Posaconazole is currently used for the prophylaxis of invasive pulmonary aspergillosis (IPA). Limitations to posaconazole usage are drug-drug interactions and side effects. PTX3 is an innate immunity glycoprotein with opsonic activity, proven to be protective in IPA animal models. This study investigated the combination of posaconazole with PTX3. The results indicate synergy between PTX3 and posaconazole against aspergillosis, suggesting that a combination of reduced doses of posaconazole with the immune response enhancer PTX3 might represent a treatment option with a higher therapeutic index than posaconazole.
authors: Takis srl, Rome, Italy marra@takisbiotech.it.
authors: Emanuele
authors: E
authors: Marra
authors: Areta International, Gerenzano, Italy.
authors: Vitor L
authors: VL
authors: Sousa
authors: University of Rome Tor Vergata, Rome, Italy.
authors: Roberta
authors: R
authors: Gaziano
authors: Takis srl, Rome, Italy.
authors: M Lucrezia
authors: ML
authors: Pacello
authors: Takis srl, Rome, Italy.
authors: Brunilde
authors: B
authors: Arseni
authors: Takis srl, Rome, Italy.
authors: Luigi
authors: L
authors: Aurisicchio
authors: Sigma-tau S.p.A, Pomezia, Italy.
authors: Rita
authors: R
authors: De Santis
authors: Sigma-tau S.p.A, Pomezia, Italy.
authors: Giovanni
authors: G
authors: Salvatori
mesh_terms: D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology*; D002097:C-Reactive Protein / Q000494:pharmacology*; D004357:Drug Synergism; D055744:Invasive Pulmonary Aspergillosis / Q000188:drug therapy*; D008297:Male; D051381:Rats; D000683:Serum Amyloid P-Component / Q000494:pharmacology*; D014230:Triazoles / Q000494:pharmacology*; D000099153:Pentraxins
chemical_list: D000935:Antifungal Agents; D002097:C-Reactive Protein; D000683:Serum Amyloid P-Component; D014230:Triazoles; D000099153:Pentraxins; C101425:posaconazole